Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Официальное название

Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta

Обзор

The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD). The primary objective of Phase 1 of this study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants. The primary objective of Phase 2 of this study is to evaluate the efficacy and safety of the multiple escalating doses of GS-4321 in participants with CHD.

Вмешательства

• Препарат GS-4321
  Administered subcutaneous (SC) or intravenously IV
• Препарат GS-4321 Placebo
  Administered SC
• Препарат GS-4321
  Administered SC

Первичные конечные точки

• Phase 1 and 2: Percentage of Participants With Treatment-emergent Adverse Events [Срок оценки: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up]
• Phase 1 and 2: Percentage of Participants With Treatment-emergent Serious Adverse Events [Срок оценки: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up]
• Phase 1 and 2: Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities [Срок оценки: Phase 1: First dose up to 44 weeks; Phase 2: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up]
• Phase 1: Serum Pharmacokinetic (PK) parameter; AUC of GS-4321 [Срок оценки: First dose up to 24 Weeks]
• Phase 1: Serum PK Parameter: Cmax [Срок оценки: First dose up to 24 Weeks]
• Phase 1: Serum PK Parameter: Tmax [Срок оценки: First dose up to 24 Weeks]
• Phase 1: Serum PK Parameter: t1/2 [Срок оценки: First dose up to 24 Weeks]
• Phase 2: Proportion of Participants with Combined Response [Срок оценки: Up to 96 Weeks]

Вторичные конечные точки (12)

• Phase 1: Proportion of Participants who Develop Antidrug Antibody (ADAs) After Administration of a Single Dose of GS-4321 and ADA Titer Characterization [Срок оценки: First dose up to 24 Weeks]
• Phase 2: Serum PK Parameters AUC of GS-4321 [Срок оценки: Up to 96 weeks]
• Phase 2: Serum PK Parameters Cmax of GS-4321 [Срок оценки: Up to 96 Weeks]
• Phase 2: Serum PK Parameters Tmax of GS-4321 [Срок оценки: Up to 96 Weeks]
• Phase 2: Serum PK Parameters Ctrough of GS-4321 [Срок оценки: Up to 96 Weeks]
• Phase 2: Proportion of Participants With Undetectable HDV RNA or ≥ 2 log10 Decrease in HDV RNA From Baseline and normal ALT (ALT < ULN). [Срок оценки: Weeks 4, 8, 12, 16, 20, 36, 48, 60, 72, 84, and 96]
• Phase 2: Change From Baseline in HDV RNA [Срок оценки: Baseline, Weeks 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, and 96]
• Phase 2: Proportion of Participants With Undetectable HDV RNA [Срок оценки: Weeks 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, and 96]
• Proportion of Participants With undetectable HDV RNA or ≥ 2 log10 Decrease in HDV From Baseline [Срок оценки: Weeks 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84 and 96]
• Phase 2: Change From Baseline in Liver Stiffness by Elastography [Срок оценки: Weeks 24, 48, and 96]
• Phase 2: Proportion of Participants with normal ALT [Срок оценки: Weeks 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, and 96]
• Phase 2: Proportion of Participants who Develop ADAs After Administration of Multiple Doses of GS-4321 and ADA Titer Characterization [Срок оценки: First dose up to 96 Weeks plus 48 weeks of posttreatment follow-up]

Критерии участия

Критерии включения

Part A:

• Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
• Have a body mass index (BMI) of ≤ 30.0 kg/m2 at screening and at admission.

Part B:

• Participants assigned male or female at birth who are of childbearing potential and engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
• Chronic hepatitis delta (CHD) for ≥ 6 months prior to screening, documented by prior medical history.
• Must be receiving a commercially available entecavir, TAF, or TDF for the treatment of hepatitis B virus (HBV) infection at or prior to enrollment. Coformulation as part of a fixed-dose combination for the treatment of HIV is permitted.
• Non-cirrhotic or compensated cirrhosis.
• Hepatitis delta virus ribonucleic acid (HDV RNA ) > 500 IU/mL at screening.
• Alanine aminotransferase (ALT) level > 1 × Upper limit of normal (ULN), but < 10 × ULN at screening.

Критерии исключения

Part A:

• Positive serum or urine pregnancy test.
• Participants with plans to breastfeed during the study period.

Part B:

• Positive serum or urine pregnancy test.
• Participants with plans to breastfeed during the study period.
• Current or previous clinically decompensated liver disease, including coagulopathy, hepatic encephalopathy, and esophageal varices hemorrhage due to HDV or HBV.
• Child-Turcotte-Pugh (CTP)-B or -C or a CTP score of ≥ 7.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Нерандомизированное

Модель

Последовательный дизайн

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

США · 4 центра

• Investigative Site — Anaheim
• University of Louisville, Clinical Trials Unit — Louisville
• University of Maryland, Institute of Human Virology, Clinical Research Unit — Baltimore
• The New York-Presbyterian Hospital — New York

Румыния · 4 центра

• Institutul National De Boli Infectioase Prof. Dr. Matei Bals — Bucharest
• Fundatia Dr. Victor Babes — Bucharest
• Infectious Diseases Institutul National De Boli Infectioase Prof. Matei Bals — Bucharest
• Gastromedica S.R.L. — Iași

South Korea · 4 центра

• Korea University Ansan Hospital — Ansan-si
• The Catholic University of Korea Bucheon St. Mary's Hospital — Bucheon-si
• The Catholic University of Korea, Seoul St. Mary's Hospital — Seoul
• Samsung Medical Center — Seoul

Тайвань · 4 центра

• Ditmanson Medical Foundation Chia-Yi Christian Hospital — Chiayi City
• Kaohsiung Medical University Chung-Ho Memorial Hospital — Kaohsiung City
• Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City
• National Taiwan University Hospital — Taipei

Moldova · 3 центра

• IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba" — Chinsinau
• IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba" — Chisinau
• PMSI Clinical Republican Hospital "Timofei Mosneaga" — Chisinau

Болгария · 1 центр

• University Multi-profile Hospital for Active Treatment "SofiaMed" 00D — Sofia

Германия · 1 центр

• Medizinische Hochschule Hannover — Hanover

Италия · 1 центр

• Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, SC Gastroenterologia ed Epatolog — Milan

Идентификаторы

NCT: NCT07096193 · GS-US-567-6968 · 2025-522729-36

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗